Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure Four months after symptom onset(A) Two fluorodeoxyglucose positive left inguinal lymph nodes. Four months after symptom onset(A) Two fluorodeoxyglucose.

Published byKarolina Samuelsson Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure Four months after symptom onset(A) Two fluorodeoxyglucose positive left inguinal lymph nodes. Four months after symptom onset(A) Two fluorodeoxyglucose."— Presentation transcript:

1 Figure Four months after symptom onset(A) Two fluorodeoxyglucose positive left inguinal lymph nodes.
Four months after symptom onset(A) Two fluorodeoxyglucose positive left inguinal lymph nodes. (B) CT pelvis showing 2 enlarged inguinal lymph nodes: posterior node is 24 × 19 mm, anterior node is 16 × 13 mm. (C) Inguinal lymphadenectomy showing high-grade neuroendocrine carcinoma (hematoxylin & eosin staining, 400× magnification). (D) Immunohistochemical staining for CK20 showing perinuclear “dot-like” staining, characteristic of Merkel cell carcinoma (400× magnification). Cen Zhang et al. Neurol Neuroimmunol Neuroinflamm 2014;1:e17 © 2014 American Academy of Neurology

Download ppt "Figure Four months after symptom onset(A) Two fluorodeoxyglucose positive left inguinal lymph nodes. Four months after symptom onset(A) Two fluorodeoxyglucose."

Similar presentations

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)
Figure 2 Medial occipital lobe (designated by visual cortical brain regions) hypometabolism in anti–NMDA receptor encephalitis Medial occipital lobe (designated.

Figure 2 Medial occipital lobe (designated by visual cortical brain regions) hypometabolism in anti–NMDA receptor encephalitis Medial occipital lobe (designated.
Figure 1 Box plot of the venous diameter in lesions

Figure 1 Box plot of the venous diameter in lesions
Figure 3 Perimysial and muscle fiber pathology in HMGCR antibody–associated myopathy (A) Perimysial pathology with histiocytic cells and widening (hematoxylin.

Figure 3 Perimysial and muscle fiber pathology in HMGCR antibody–associated myopathy (A) Perimysial pathology with histiocytic cells and widening (hematoxylin.
Figure 1 Muscle biopsy from a patient with a slowly progressive (24 years) HMGCR antibody–associated myopathy syndrome (A) Hematoxylin & eosin stain, (B)

Figure 1 Muscle biopsy from a patient with a slowly progressive (24 years) HMGCR antibody–associated myopathy syndrome (A) Hematoxylin & eosin stain, (B)
Figure Vertebral artery angiogram and tissue pathology

Figure Vertebral artery angiogram and tissue pathology
Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.

Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.
Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.

Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.

Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.
Figure 2 Optical coherence tomography of the human retina A) Detailed retinal segmentation sample on spectral-domain optical coherence tomography (OCT)

Figure 2 Optical coherence tomography of the human retina A) Detailed retinal segmentation sample on spectral-domain optical coherence tomography (OCT)
Figure 2 Immunopathologic analysis of all 3 Rasmussen encephalitis cases Immunopathologic analysis of all 3 Rasmussen encephalitis cases (A) Perivascular.

Figure 2 Immunopathologic analysis of all 3 Rasmussen encephalitis cases Immunopathologic analysis of all 3 Rasmussen encephalitis cases (A) Perivascular.
Figure 1 Muscle biopsy images demonstrating a pauci-immune necrotizing autoimmune myopathy in illustrative cases 1 and 2 (A–D) Case 1 deltoid muscle. Muscle.

Figure 1 Muscle biopsy images demonstrating a pauci-immune necrotizing autoimmune myopathy in illustrative cases 1 and 2 (A–D) Case 1 deltoid muscle. Muscle.
Figure Brain MRI and biopsy specimens from the pontine lesion

Figure Brain MRI and biopsy specimens from the pontine lesion
Figure Radiologic and histopathologic findings in a patient with IgG4-related intracranial hypertrophic pachymeningitis(A–D) Radiologic findings over 10.

Figure Radiologic and histopathologic findings in a patient with IgG4-related intracranial hypertrophic pachymeningitis(A–D) Radiologic findings over 10.
Figure 1 Histopathologic features of case 1 (A–G) and case 2 (H–L)‏

Figure 1 Histopathologic features of case 1 (A–G) and case 2 (H–L)‏
Figure 2 Neuropathologic examination for lymphoma etiology (patients 1–4)‏ Neuropathologic examination for lymphoma etiology (patients 1–4) Immunohistochemical.

Figure 2 Neuropathologic examination for lymphoma etiology (patients 1–4)‏ Neuropathologic examination for lymphoma etiology (patients 1–4) Immunohistochemical.
Figure 4 Comparison of 7.0T and 3.0T MRI (patients 5 and 6)‏

Figure 4 Comparison of 7.0T and 3.0T MRI (patients 5 and 6)‏
Figure 1 Neuropathologic examination of brain areas with normal MRI appearance and with gadolinium enhancement (patient 1)‏ Neuropathologic examination.

Figure 1 Neuropathologic examination of brain areas with normal MRI appearance and with gadolinium enhancement (patient 1)‏ Neuropathologic examination.
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Similar presentations

Ads by Google